The present invention provides an application of tannic acid in preparing a medicament against respiratory viruses. The present invention show through live virus experiments that tannic acid has a significant inhibitory effect on respiratory viruses including SARS-CoV-2 coronavirus, Influenza A H1N1 virus, etc., with an exact curative effect, and thus has a broad application prospect in the field of preparation of medicaments against respiratory viruses. In addition, tannic acid exists in a variety of plants, which is a natural active compound existing in nature, and has also been used as a food additive, with a high safety and good foundation for medicament development.

The present invention provides an application of tannic acid in preparing a medicament against respiratory viruses. The present invention show through live virus experiments that tannic acid has a significant inhibitory effect on respiratory viruses including SARS-CoV-2 coronavirus, Influenza A H1N1 virus, etc., with an exact curative effect, and thus has a broad application prospect in the field of preparation of medicaments against respiratory viruses. In addition, tannic acid exists in a variety of plants, which is a natural active compound existing in nature, and has also been used as a food additive, with a high safety and good foundation for medicament development.

Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising:at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; at least one chelating agent; at least one source of peroxidative radicals; at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising:at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; at least one chelating agent; at least one source of peroxidative radicals; at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising:at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; at least one chelating agent; at least one source of peroxidative radicals; at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.

The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.